Evidence map›Paper›PMID 34452206›Full record

ArticlePharmaceutics2021

Ultrasound-Mediated Blood-Brain Barrier Opening Improves Whole Brain Gene Delivery in Mice.

Marie-Solenne Felix, Emilie Borloz, Khaled Metwally, Ambre Dauba, Benoit Larrat, Valerie Matagne, Yann Ehinger, Laurent Villard, Anthony Novell, Serge Mensah and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Focused ultrasound expands intra-CSF AAV delivery to deep brain regions in rats and non-human primates.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  3. Review
  4. Article
  5. Erasable serum markers.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. State-of-the-art therapies for Rett syndrome.Developmental medicine and child neurology · 2023
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Marie-Solenne FelixAix Marseille Univ., INSERM, MMG, U1251, Faculté de Médecine Timone, 13385 Marseille, France.
Emilie BorlozAix Marseille Univ., INSERM, MMG, U1251, Faculté de Médecine Timone, 13385 Marseille, France.ORCID 0000-0001-6983-6461
Khaled MetwallyAix Marseille Univ., CNRS, Centrale Marseille, LMA UMR 7031, 13013 Marseille, France.
Ambre DaubaUniversité Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, 91401 Orsay, France.
Benoit LarratUniversité Paris-Saclay, CNRS, CEA, DRF/JOLIOT/NEUROSPIN/BAOBAB, 91191 Gif-sur-Yvette, France.ORCID 0000-0003-1577-6293
Valerie MatagneAix Marseille Univ., INSERM, MMG, U1251, Faculté de Médecine Timone, 13385 Marseille, France.
Yann EhingerAix Marseille Univ., INSERM, MMG, U1251, Faculté de Médecine Timone, 13385 Marseille, France.
Laurent VillardAix Marseille Univ., INSERM, MMG, U1251, Faculté de Médecine Timone, 13385 Marseille, France.
Anthony NovellUniversité Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, 91401 Orsay, France.ORCID 0000-0003-3649-0956
Serge MensahAix Marseille Univ., CNRS, Centrale Marseille, LMA UMR 7031, 13013 Marseille, France.
Jean-Christophe RouxAix Marseille Univ., INSERM, MMG, U1251, Faculté de Médecine Timone, 13385 Marseille, France.ORCID 0000-0002-9721-8844
Inserm · FRCentre National de la Recherche Scientifique · FR

Funding

ANR DROPMUT grant ANR-19-CE19-0011CSRD VA 1plan cancer project GRAVITY PC201613
6 · The paper itself

Abstract

Gene therapy represents a powerful therapeutic tool to treat diseased tissues and provide a durable and effective correction. The central nervous system (CNS) is the target of many gene therapy protocols, but its high complexity makes it one of the most difficult organs to reach, in part due to the blood-brain barrier that protects it from external threats. Focused ultrasound (FUS) coupled with microbubbles appears as a technological breakthrough to deliver therapeutic agents into the CNS. While most studies focus on a specific targeted area of the brain, the present work proposes to permeabilize the entire brain for gene therapy in several pathologies. Our results show that, after i.v. administration and FUS sonication in a raster scan manner, a self-complementary AAV9-CMV-GFP vector strongly and safely infected the whole brain of mice. An increase in vector DNA (19.8 times), GFP mRNA (16.4 times), and GFP protein levels (17.4 times) was measured in whole brain extracts of FUS-treated GFP injected mice compared to non-FUS GFP injected mice. In addition to this increase in GFP levels, on average, a 7.3-fold increase of infected cells in the cortex, hippocampus, and striatum was observed. No side effects were detected in the brain of treated mice. The combining of FUS and AAV-based gene delivery represents a significant improvement in the treatment of neurological genetic diseases.

Indexed as

AAV9blood-brain barrierfocused ultrasoundgene therapymicrobubbles

Identifiers

PMID34452206
PMCPMC8399273
OpenAlexW3189013407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.